Details

Autor(en) / Beteiligte

• Ren, Hu
• Zhang, Jian-Wei
• Lan, Zhong-Min
• Du, Yong-Xing
• Qiu, Guo-Tong
• Zhang, Li-Peng
• Gu, Zong-Ting
• Li, Zong-Ze
• Li, Guang
• Shao, Hai-Bo
• Ju, Zhong-Jian
• Yu, Wei
• Qu, Bao-Lin
• Xu, Ke
• Wang, Cheng-Feng

Titel

Intraoperative radiotherapy vs concurrent chemoradiotherapy in the treatment of patients with locally advanced pancreatic cancer

Ist Teil von

• Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2021-09, Vol.21 (6), p.1052-1058

Ort / Verlag

Switzerland: Elsevier B.V

Erscheinungsjahr

2021

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• The purpose of the multi-institutional retrospective study was to evaluate whether intraoperative radiotherapy (IORT) has advantages in the treatment of patients with locally advanced pancreatic cancer (LAPC) compared with concurrent chemoradiotherapy (CCRT). A total of 103 patients with LAPC whom was treated with IORT (Arm A; n = 50) or CCRT (Arm B; n = 53) from 2015.6 to 2016.7 were retrospectively identified. Data on feasibility, toxicity, and overall survival (OS) were evaluated. Most factors of the two cohorts were similar. The severe adverse events (grade 3 and 4) patients in Arm B were higher than patients in Arm A (34% vs 0%). Disease progression was noted in 38 patients (76%) in Arm A and 37 patients (69.8%) in Arm B. The median survival of patients in Arm A and B were 15.3 months (95% CI, 13.0–17.6 months) and 13.8 months (95% CI, 11.0–16.6 months), respectively. The 1-year survival rate were 66.3% in Arm A (95% CI, 52.3%–80.2%) and 60.9% in Arm B (95% CI, 46.4%–75.4%). There was no significant difference in OS between patients treated with IORT and with CCRT (p = 0.458). Our results demonstrated that patients with LAPC treated with IORT showed fewer adverse events, less treatment time, and high feasibility compared to CCRT. Although, IORT has no advantages in survival and tumor control compared with CCRT.